Home » Stocks » KTOV

Kitov Pharma Ltd. (KTOV)

Stock Price: $4.18 USD -0.07 (-1.65%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $4.26 +0.08 (1.91%) Dec 3, 7:43 PM

Stock Price Chart

Key Info

Market Cap 719.40M
Revenue (ttm) 1,000,000
Net Income (ttm) -5.89M
Shares Out 1.94M
EPS (ttm) -7.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $4.18
Previous Close $4.25
Change ($) -0.07
Change (%) -1.65%
Day's Open 4.22
Day's Range 4.13 - 4.29
Day's Volume 249,604
52-Week Range 0.23 - 4.73

More Stats

Market Cap 719.40M
Enterprise Value 713.23M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 1.94M
Float n/a
EPS (basic) -3.00
EPS (diluted) -7.80
FCF / Share -2.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 43,954
Short Ratio 0.11
Short % of Float n/a
Beta 2.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 719.40
PB Ratio 1.25
Revenue 1,000,000
Operating Income -7.16M
Net Income -5.89M
Free Cash Flow -5.59M
Net Cash 6.17M
Net Cash / Share 0.04
Gross Margin 100.00%
Operating Margin -715.60%
Profit Margin -589.30%
FCF Margin -559.20%
ROA -9.15%
ROE -92.04%
ROIC -572.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$25.00*
Low
25.0
Current: $4.18
High
25.0
Target: 25.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue1.001.000.10----
Revenue Growth0%900%-----
Gross Profit1.001.000.10----
Operating Income-7.16-7.83-11.97-7.18-4.07-4.46-2.55
Net Income-5.89-5.57-12.91-12.13-4.20-5.25-2.63
Shares Outstanding1.941.420.950.580.100.020.01
Earnings Per Share-3.00-3.90-13.70-21.10-44.00-234.00-320.00
Operating Cash Flow-5.58-8.48-8.63-6.26-3.31-4.53-0.51
Capital Expenditures-0.01-0.02-0.01-0.01-0.01--
Free Cash Flow-5.59-8.50-8.64-6.27-3.32-4.53-0.51
Cash & Equivalents6.406.687.4414.6610.561.310.19
Total Debt0.220.552.01-0.140.370.78
Net Cash / Debt6.176.135.4214.6610.420.94-0.59
Assets14.7214.7214.1814.9110.811.760.31
Liabilities3.863.725.501.531.380.991.26
Book Value10.4210.527.4113.399.430.77-0.95
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kitov Pharma Ltd.
Employees 9
CEO Itzhak Israel

Stock Information

Ticker Symbol KTOV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KTOV

Description

Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd is headquartered in Tel Aviv, Israel.